{"type":"trials","record":{"id":42196,"source_id":"clinicaltrials-gov","external_id":"NCT05678517","title":"Seven-year Outcomes Following Intensive Anti-VEGF Therapy in Wet AMD","brief_summary":"The aim of this study was to assess long-term benefits of intensive aflibercept and ranibizumab anti-VEGF therapy in patients with exudative AMD.","overall_status":"Completed","phases":[],"study_type":"OBSERVATIONAL","sponsor":"Semmelweis University","enrollment":47,"countries":["Hungary"],"start_date":"2010-01-01","completion_date":"2022-12-06","last_update_date":"2023-01-10","source_url":"https://clinicaltrials.gov/study/NCT05678517","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years","comparator":null,"organization":"Semmelweis University","interventions":["Anti-VEGF"],"registry_source":"ClinicalTrials.gov","outcome_measures":["BCVA — At the end of follow-up (year 7)","Geographic atrophy — At the end of follow-up (year 7)","Retinal fluid — At the end of follow-up (year 7)","Number of injections — Over the course of the follow-up (7 years)","Adverse events — Over the course of the follow-up (7 years)"],"design_description":null,"source_has_results":false},"controlled_terms":["Age-Related Macular Degeneration","Anti-VEGF"],"relevance_confidence":60,"source_quality_score":100,"freshness_score":50,"publication_state":"published","match_explanation":"Source terminology contains: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct05678517","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2010-01-01 to 2022-12-06","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.933Z","intervention":["Anti-VEGF"],"participants":47,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["BCVA — At the end of follow-up (year 7)","Geographic atrophy — At the end of follow-up (year 7)","Retinal fluid — At the end of follow-up (year 7)","Number of injections — Over the course of the follow-up (7 years)","Adverse events — Over the course of the follow-up (7 years)"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Source terminology contains: age-related macular degeneration.","Source terminology supplies longevity context: age-related.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["controlled terminology","controlled context","study type"],"relevance_score":60,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42196","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}